Separately, the WSJ reports that Rodman & Renshaw doesn't expect Afrezza to get another shot at approval for two years and estimates MNKD will need $150-200 million to get there.
"MannKind (MNKD) is down after it said it is eliminating 41 percent of its staff, 179 employees, following notification from the U.S. Food and Drug Administration that it would not approve the company's experimental inhaled insuli
